FULC at a glance
Fulcrum Therapeutics, Inc. (FULC, SEC CIK 1680581) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as July 20, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Fulcrum Therapeutics, Inc. (FULC) reported revenue of $0 (down 100.0% from FY2024) and a net loss of $74.9 million. Diluted EPS was -$1.18.
- As of September 30, 2026, 25 institutional investment managers tracked by SignalX reported holding Fulcrum Therapeutics, Inc. (FULC) shares worth $111.2 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by TANG KEVIN on July 17, 2026 of 50,945 shares at $3.52 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $0
- −100.0% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 25 funds
- $111.2M · +1 vs prior quarter
- Latest 8-K
- Nov 12, 2026
- Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- Smaller reporting company status: Item 1A risk-factor disclosure omitted under Rule 12b-2
- No newly added, updated, regulatory, operational, competitive, market, or financial risks disclosed this quarter
Management Discussion & Analysis
- Quarterly revenue $0, unchanged YoY, with no product sales
- Net loss $10.9M vs $19.6M YoY, operating expenses $13.9M vs $21.9M
- Pociredir R&D expenses $1.9M vs $5.4M YoY, the largest program expense
- Cash, equivalents and securities $306.5M at September 30, 2026
- Operating cash used $48.2M vs $43.3M YoY, merger expected Q4 2026 with $275M dividend and $7.0M asset sale
AI summary of the FULC 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- Fulcrum agreed to sell early-stage HbF assets for approximately $7.0 million in cash
- Closing depends on the proposed Fulcrum-Slate merger, or necessary approvals if the merger terminates
Item EX-99.1: Item EX-99.1
- All-stock merger shifts Fulcrum into Slate Medicines, focusing the public company on migraine therapeutics
- Fulcrum holders expected to own 5.0%; Slate holders 95.0%, subject to adjustment based on Fulcrum net cash
Item 5.01: Changes in Control of Registrant
- Item 5.01 cross-references Item 1.01 for any control-change information
- Investor impact depends on the transaction details disclosed under Item 1.01
Item EX-99.2: Item EX-99.2
- Proposed stock-for-stock merger creates Slate Medicines, with Fulcrum holders receiving an estimated 5.0% of the combined company
- $245 million private placement led by Frazier Life Sciences, funding Slate’s migraine pipeline and materially reshaping Fulcrum’s capital structure
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Item 5.02 contains no standalone officer or director change details
- Investor-relevant information is incorporated from Item 1.01, requiring review of the material agreement terms
Item 7.01: Regulation FD Disclosure
- Fulcrum and Slate announced execution of a merger agreement and purchase agreement on August 17, 2026
- Transaction terms include exchange-ratio adjustments tied to Fulcrum’s closing net cash, affecting ownership and potential cash distributions
Item 1.01: Entry into a Material Definitive Agreement
- Merger transforms Fulcrum into Slate Medicines, with Slate holders owning 55.9% and existing Fulcrum holders only 5.0% fully diluted
- $245.0M concurrent investment provides planned capitalization, with investors receiving 39.1% of the combined company
Item 3.02: Unregistered Sales of Equity Securities
- Slate shares issued in Concurrent Investment through private placements, exempt from SEC registration under Section 4(a)(2) and/or Regulation D
- Unregistered issuance limits immediate public offering requirements but may create future dilution for existing Fulcrum shareholders
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Principal accounting officer Greg Tourangeau departing Fulcrum on August 7, 2026
- CFO Alan Musso appointed principal accounting officer effective August 7, 2026
AI summaries of FULC 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for FULC
Don't miss the next FULC filing
- Alerts as it files. A push when FULC files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut FULC, by share count.
- Ask anything. An AI agent that reads every FULC filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| TANG KEVIN | Buy | Jul 17, 2026 | 50,945 | $3.52 |
| TANG KEVIN | Buy | Jul 16, 2026 | 116,671 | $3.56 |
| TANG KEVIN | Buy | Jul 15, 2026 | 107,377 | $3.56 |
| TANG KEVIN | Buy | Jul 14, 2026 | 53,651 | $3.56 |
| TANG KEVIN | Buy | Jul 14, 2026 | 75,952 | $3.58 |
| TANG KEVIN | Buy | Jul 13, 2026 | 12,966 | $3.54 |
| Ezekowitz Alan | Sell | Jun 26, 2026 | 18,000 | $3.65 |
| Lehrer-Graiwer Joshua | A | Apr 23, 2026 | 64,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $2.8M | $80.0M | $0 |
| Operating Income | -$110.7M | -$21.9M | -$84.8M |
| Net Income | -$97.3M | -$9.7M | -$74.9M |
| Op. Margin | -3945.2% | -27.4% | - |
| Net Margin | -3470.1% | -12.2% | - |
| Balance Sheet | |||
| Total Assets | - | $260.7M | $366.3M |
| Equity | - | $243.0M | $349.0M |
| ROE | - | -4.0% | -21.5% |
| Per Share | |||
| EPS | $-1.59 | $-0.16 | $-1.18 |
| Cash Flow | |||
| Operating CF | - | -$2.2M | -$60.1M |
| CapEx | - | $278K | $314K |
Source: XBRL data in Fulcrum Therapeutics, Inc. (FULC)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate FULC share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 25 | $111.2M |
| Q2 2026 | 24 | $108.2M |
| Q1 2026 | 26 | $132.3M |
| Q4 2025 | 24 | $175.7M |
| Q3 2025 | 24 | $128.8M |
| Q2 2025 | 26 | $101.2M |
| Q1 2025 | 24 | $27.1M |
| Q4 2024 | 18 | $39.3M |
- BlackRock+2.80M (+32%)
- Two Sigma Investments+1.78M (+219%)
- D.E. Shaw & Co+664.2K (+22%)
- Renaissance Technologies LLC+572.3K (+35%)
- Vanguard Capital Management LLC+168.1K (+6%)
- Citadel Advisors LLC−2.19M (-81%)
- Millennium Management−1.44M (-97%)
- AQR Capital Management−933.1K (-85%)
- State Street Corp−759.1K (-37%)
- Goldman Sachs Group−337.8K (-31%)
- Prudential Financial+151.0K
- Ameriprise Financial+53.2K
- FMR LLC (Fidelity)−92.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 191 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
FULC filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 12, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 12, 2026 | - | Analysis | - |
| 8-K | Aug 17, 2026 | - | Analysis | - |
| SC 13G | Aug 14, 2026 | - | - | |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| SC 13G | Aug 3, 2026 | - | - | |
| 10-Q | Jul 30, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 20, 2026 | - | - | - |
| SC 13G | Jul 17, 2026 | - | - | |
| 4 | Jul 15, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| SC 13G | Jun 25, 2026 | - | - | |
| SC 13G | Jun 25, 2026 | - | - | |
| 8-K | Jun 25, 2026 | - | Analysis | - |
| 8-K | Jun 11, 2026 | - | Analysis | - |
| SC 13G | Jun 10, 2026 | - | - | |
| 8-K | Jun 4, 2026 | - | Analysis | |
| 8-K | Jun 1, 2026 | - | Analysis | |
| 4 | May 1, 2026 | - | - | - |
| 8-K | Apr 27, 2026 | - | Analysis | - |
| 10-Q | Apr 27, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Feb 24, 2026 | - | Analysis | - |
| 10-K | Feb 24, 2026 | Dec 31, 2025 | - | |
| 4 | Feb 4, 2026 | - | - | |
| 4 | Feb 4, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
FULC SEC filings: frequently asked questions
Which institutions hold FULC stock?
As of September 30, 2026, the largest Fulcrum Therapeutics, Inc. (FULC) holders among the 13F filers tracked by SignalX were BlackRock ($43.0 million), D.E. Shaw & Co ($13.7 million), Vanguard Capital Management LLC ($10.6 million), Two Sigma Investments ($9.6 million), Renaissance Technologies LLC ($8.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was FULC's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Fulcrum Therapeutics, Inc. (FULC) reported revenue of $0 (down 100.0% from FY2024) and a net loss of $74.9 million. Diluted EPS was -$1.18. The figures come from the XBRL data in the 10-K.
What did FULC report in its latest 8-K?
Fulcrum Therapeutics, Inc. (FULC) filed an 8-K on November 12, 2026 reporting Item 8.01 (Other Events). Fulcrum agreed to sell early-stage HbF assets for approximately $7.0 million in cash.
What are the latest FULC SEC filings?
Fulcrum Therapeutics, Inc. (FULC) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on July 20, 2026.
What is FULC's SEC CIK number?
Fulcrum Therapeutics, Inc. (FULC)'s SEC Central Index Key (CIK) is 1680581. EDGAR lists every FULC filing under that number.
Ask anything about FULC
The research agent reads FULC's filings, financials, insider trades and 13F holders, then answers with sources.